Enrollment for the 375+ subject trial was completed in March 2007 and an analysis of the full study results is planned for the second half of the year. The interim findings from BRITE are encouraging in that they are consistent with results from prior studies suggesting that there is an early brain signal of response to antidepressant treatment.”

Interim BRITE study results indicate that Aspect’s Antidepressant Treatment Response (ATR) index achieved statistical significance in predicting seven week clinical response as measured by the standard Hamilton depression Rating Scale after just one week on treatment with an SSRI. “These findings propose that the ATR index may additionally help us identify the right antidepressant treatment to supply relief for patients,” said Dr.

The interim findings propose that the EEG-based technology is a significant predictor of patient response to a selective serotonin reuptake inhibitor (SSRI) after only one week of treatment. Further, the results propose that BRITE may help expedite the process of identifying effective antidepressant drug therapy. “Given that the current trial and error approach to finding an efficacious regimen typically takes many weeks, having the ability to determine treatment response more quickly would be an crucial clinical advance.

“These interim BRITE trial results are encouraging and support our belief that we can develop a

practical, easy-to-use brain assessment device to help clinicians optimize care for patients suffering from depression,” said Nassib Chamoun, president and CEO of Aspect Medical Systems. More knowledge about the BRITE trial is available at www.brite-md.com.

“There are more than 20 antidepressants available on the market today, and all of them are effective for relieving the symptoms of depression. The problem is that the majority of patients will not reply adequately to the first antidepressant treatment they are prescribed,” said Andrew Leuchter, M.D., Professor of Psychiatry at the Semel Institute for Neuroscience and Human Behavior at UCLA, principal investigator for the trial, and chair of Aspect’s Neuroscience Advisory Board. In addition, a retrospective analysis of BRITE trial subjects demonstrated that patients who received treatment in accordance with the ATR index were significantly more likely to reply to treatment than the other patients in the trial.

Interim study results from Aspect Medical System’s BRITE (Biomarkers for Rapid Identification of Treatment Effectiveness) trial in major depression were presented at the annual meeting of the American Psychiatric organization yesterday.

Aspect is conducting the BRITE trial in collaboration with leading depression researchers at ten research facilities across the United States. Leuchter.

Original post by Anxiety Insights

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.

• 
• 
• 
• 
• 
• 
•